Cytokinetics | Des Atouts



Assets Changement Date
Acadia Pharmaceuticals USD 1.19B 210.89M 2024-12
Amgen USD 91.84B 956M 2024-12
Bayer EUR 110.85B 3.9B 2024-12
Biogen USD 28.05B 263.9M 2024-12
Bristol-Myers Squibb USD 92.6B 1.07B 2024-12
Cytokinetics USD 1.4B 34.39M 2024-12
Eisai JPY 1.43T 111.45B 2024-12
Eli Lilly USD 78.71B 3.11B 2024-12
Exelixis USD 2.95B 12.59M 2025-01
Geron USD 593.78M 148.83M 2024-12
Halozyme Therapeutics USD 2.06B 54.55M 2024-12
Intra Cellular Therapies USD 1.37B 42.47M 2024-12
Ionis Pharmaceuticals USD 3B 77.42M 2024-12
Ligand Pharmaceuticals USD 941.77M 13.09M 2024-12
Merck USD 117.11B 426M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 213.4B 6.08B 2024-12
Regeneron Pharmaceuticals USD 37.76B 317.5M 2024-12
Roche Holding CHF 101.8B 6.02B 2024-12
Sanofi 129.76B 3.29B 2024-06



Cytokinetics Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.